NLS Pharmaceutics and Kadimastem Confirm Fulfillment of Key Conditions for Merger and Set Delisting Date for Kadimastem Shares

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Oct 29 2025

0mins

Source: Newsfilter

Merger Announcement: NLS Pharmaceutics Ltd. and Kadimastem Ltd. have received Nasdaq approval for their merger, with the closing date set for October 30, 2025, and Kadimastem's shares to be delisted from the Tel Aviv Stock Exchange on October 31, 2025.
Share Exchange Ratio: The final exchange ratio for the merger is established at 7.06 NLS common shares for each Kadimastem ordinary share, which will adjust to 0.706 NLS common shares after a reverse share split.
New Company Formation: The merged entity will be named NewCelX Ltd. and will begin trading on the Nasdaq Capital Market under the ticker symbol "NCEL" starting October 31, 2025.
Forward-Looking Statements: The announcement includes forward-looking statements regarding the merger's completion and trading timelines, highlighting potential risks and uncertainties that could affect the expected outcomes.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like undefined with instant alerts to capture every critical market movement.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.